Clinical implementation of circulating tumour DNA testing for EGFR T790M for detection of treatment resistance in non-small cell lung cancer.

Tara SpenceSheron PereraJessica WeissSylvie GrenierLaura RanichFrances ShepherdTracy L Stockley

Published in: Journal of clinical pathology (2020)

The ddPCR test for EGFR T790M mutations effectively triaged 24% of patients for treatment with osimertinib, avoiding the need for invasive tissue biopsy in these patients. Our findings suggest that initial and repeat ctDNA testing can be used to monitor for acquired EGFR T790M resistance for NSCLC.

Keyphrases

small cell lung cancer
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
tyrosine kinase
healthcare
peritoneal dialysis
primary care
prognostic factors
patient reported outcomes
circulating tumor
quality improvement
replacement therapy
loop mediated isothermal amplification